178 related articles for article (PubMed ID: 32883109)
1. Real-world outcomes among US Merkel cell carcinoma patients initiating immune checkpoint inhibitors or chemotherapy.
Chandra S; Zheng Y; Pandya S; Yu T; Kearney M; Wang L; Kim R; Phatak H
Future Oncol; 2020 Nov; 16(31):2521-2536. PubMed ID: 32883109
[No Abstract] [Full Text] [Related]
2. Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel.
Cowey CL; Liu FX; Kim R; Boyd M; Fulcher N; Krulewicz S; Kasturi V; Bhanegaonkar A
Future Oncol; 2021 Jun; 17(18):2339-2350. PubMed ID: 33709776
[TBL] [Abstract][Full Text] [Related]
3. Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study.
Stege HM; Haist M; Schultheis S; Fleischer MI; Mohr P; Ugurel S; Terheyden P; Thiem A; Kiecker F; Leiter U; Becker JC; Meissner M; Kleeman J; Pföhler C; Hassel J; Grabbe S; Loquai C
Cancer Immunol Immunother; 2021 Nov; 70(11):3313-3322. PubMed ID: 33870464
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States.
Kearney M; Thokagevistk K; Boutmy E; Bharmal M
J Med Econ; 2018 Dec; 21(12):1159-1171. PubMed ID: 30149739
[TBL] [Abstract][Full Text] [Related]
5. [Immune checkpoint inhibition in Merkel cell carcinoma].
Terheyden P; Mohr A; Langan EA
Hautarzt; 2019 Sep; 70(9):684-690. PubMed ID: 31468071
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy.
Zheng Y; Yu T; Mackey RH; Gayle JA; Wassel CL; Phatak H; Kim R
Clinicoecon Outcomes Res; 2021; 13():213-226. PubMed ID: 33790597
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab and other immune checkpoint inhibitors in locally advanced or metastatic Merkel Cell Carcinoma: safety and efficacy.
Marchand A; Kervarrec T; Bhatia S; Samimi M
Expert Rev Anticancer Ther; 2020 Dec; 20(12):1093-1106. PubMed ID: 33044876
[TBL] [Abstract][Full Text] [Related]
8. T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options.
Gehrcken L; Sauerer T; Schaft N; Dörrie J
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445385
[TBL] [Abstract][Full Text] [Related]
9. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Georges S; Shah P; Ellers-Lenz B; Bajars M; Güzel G; Nghiem PT
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414862
[TBL] [Abstract][Full Text] [Related]
10. [Merkel cell carcinoma, role of radiotherapy and literature review].
Guihard S; Noël G
Cancer Radiother; 2009 Jan; 13(1):47-54. PubMed ID: 18718802
[TBL] [Abstract][Full Text] [Related]
11. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S
J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630
[TBL] [Abstract][Full Text] [Related]
12. Multimodal Strategy in Localized Merkel Cell Carcinoma: Where Are We and Where Are We Heading?
Ricco G; Andrini E; Siepe G; Mosconi C; Ambrosini V; Ricci C; Casadei R; Campana D; Lamberti G
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638968
[TBL] [Abstract][Full Text] [Related]
13. Merkel cell carcinoma.
Han SY; North JP; Canavan T; Kim N; Yu SS
Hematol Oncol Clin North Am; 2012 Dec; 26(6):1351-74. PubMed ID: 23116583
[TBL] [Abstract][Full Text] [Related]
14. Real-World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR-Merkel.
Bhanegaonkar A; Liu FX; Boyd M; Fulcher N; Kim R; Krulewicz S; Smith J; Cowey CL
Oncologist; 2021 Sep; 26(9):e1633-e1643. PubMed ID: 34101298
[TBL] [Abstract][Full Text] [Related]
15. [Merkel cell carcinoma: current diagnosis and treatment].
Mortier L; Mirabel X; Ferte C; Penel N
Bull Cancer; 2008 Sep; 95(9):823-7. PubMed ID: 18829415
[TBL] [Abstract][Full Text] [Related]
16. [Periocular Merkel Cell Carcinoma - an overview of clinical aspects and current therapeutic options].
Esser E; Grünewald I; Mihailovic N
Laryngorhinootologie; 2024 Jun; 103(6):404-412. PubMed ID: 38128577
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab.
Bharmal M; Nolte S; Lebbé C; Mortier L; Brohl AS; Fazio N; Grob JJ; Pusceddu S; Hanna GJ; Hassel JC; Kiecker F; Ellers-Lenz B; Bajars M; Güzel G; Nghiem P; Hunger M; Schlichting M; Henry-Szatkowski M; D'Angelo SP
Future Oncol; 2020 Sep; 16(27):2089-2099. PubMed ID: 32938212
[No Abstract] [Full Text] [Related]
18. Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs.
Schadendorf D; Lebbé C; Zur Hausen A; Avril MF; Hariharan S; Bharmal M; Becker JC
Eur J Cancer; 2017 Jan; 71():53-69. PubMed ID: 27984768
[TBL] [Abstract][Full Text] [Related]
19. Current and preclinical treatment options for Merkel cell carcinoma.
Celikdemir B; Houben R; Kervarrec T; Samimi M; Schrama D
Expert Opin Biol Ther; 2023; 23(10):1015-1034. PubMed ID: 37691397
[TBL] [Abstract][Full Text] [Related]
20. [Severe necrotizing myopathy subsequent to Merkel cell carcinoma].
Hocar O; Poszepczynska-Guigné E; Faye O; Wechsler J; Bagot M; Buffard V
Ann Dermatol Venereol; 2011 Feb; 138(2):130-4. PubMed ID: 21333825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
